<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445776/" ref="ordinalpos=404&amp;ncbi_uid=5305730&amp;link_uid=PMC3445776" image-link="/pmc/articles/PMC3445776/figure/F1/" class="imagepopup">figure 1.  From: Molecular Pathways: The Hedgehog <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span> in Cancer. </a></div><br /><div class="p4l_captionBody">The Hedgehog signaling pathway. Positive and negative regulatory components are depicted in green and red, respectively. A. In the absence of HH ligand, PTCH1 inhibits SMO allowing the GLI processing complex containing SUFU to generate GLIr transcriptional repressors. B. HH ligand binding to PTCH depresses SMO and generates GLIa nuclear factors that induce the expression of Hh target genes. Clinical and preclinical inhibitors of pathway signaling are listed at their sites of pathway activity.</div></div>